novo glp-1 Novo, Lilly buoyed by fast-growing drug sales What's next for GLP-1 innovation:

These values are defined as follows: 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain and 4 = very severe pain

Speak to Analyst: Customize insights for your business strategy: Regional Outlook and Growth Opportunities The market demonstrates strong regional expansion trends: USA (17.1% CAGR): Leading commercialization and structured nutrition adoption UK (15.6% CAGR): Strong DTC nutrition ecosystem and meal replacement familiarity Germany (15.0% CAGR): Premium wellness and pharmacy-adjacent demand growth Japan (14.2% CAGR): Smaller-format convenience nutrition innovation South Korea (14.8% CAGR): Growth in functional wellness beverages and meal solutions North America remains the leading commercialization hub, while Europe and East Asia continue driving premiumization and innovation in portion-controlled nutrition formats

GLP-1 receptor activation improves B cell function and survival following induction of endoplasmic reticulum stress

Injection site reactions such as rash, erythema, or itching are common with GLP-1 RA use

Ozempic is not FDA-approved for weight loss